Literature DB >> 9616519

Intermediate alpha 1-antitrypsin deficiency PiSZ: a risk factor for pulmonary emphysema?

N Seersholm1, A Kok-Jensen.   

Abstract

It is well documented that the severe hereditary disorder alpha 1-antitrypsin deficiency (alpha 1ATD) PiZZ is a strong risk factor for emphysema, especially among smokers, but the role of intermediate alpha 1ATD PiMZ and PiSZ in the development of emphysema remains uncertain. In this study, we have evaluated mortality and lung function of 94 persons with intermediate alpha 1ATD PiSZ of whom 66 were non-index cases, i.e. persons ascertained through family studies. The index cases and the non-index cases were similar with respect to sex, age and follow-up time, but differed in smoking habits and FEV1. Among the smokers there was no significant difference in pack-years between index cases and non-index cases. The overall Standardized Mortality Ratio (SMR) was 1.6 (95% confidence intervals (CI): 0.8-2.7). For the index cases the SMR was 4.3 (95% CI: 1.9-8.5) and for the non-index cases it was 0.8 (95% CI: 0.3-1.8). In the index group six patients died of pulmonary emphysema, one of pulmonary fibrosis, and one of colon cancer. In the non-index group two died of pulmonary emphysema, two of pneumonia, and one of cerebral haemorrhage. The mean initial FEV1% predicted among the index cases was 59% compared with 94% among the non-index cases. Based on the analysis of the non-index cases it is concluded that only a small fraction of persons with the PiSZ phenotype are at increased risk of developing pulmonary emphysema, and at an older age than persons with the PiZ phenotype.

Entities:  

Mesh:

Year:  1998        PMID: 9616519     DOI: 10.1016/s0954-6111(98)90102-0

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  6 in total

Review 1.  Chronic obstructive pulmonary disease in alpha1-antitrypsin PI MZ heterozygotes: a meta-analysis.

Authors:  C P Hersh; M Dahl; N P Ly; C S Berkey; B G Nordestgaard; E K Silverman
Journal:  Thorax       Date:  2004-10       Impact factor: 9.139

Review 2.  Alpha1-antitrypsin deficiency. 1: epidemiology of alpha1-antitrypsin deficiency.

Authors:  M Luisetti; N Seersholm
Journal:  Thorax       Date:  2004-02       Impact factor: 9.139

3.  Clarifying the Risk of Lung Disease in SZ Alpha-1 Antitrypsin Deficiency.

Authors:  Alessandro N Franciosi; Brian D Hobbs; Oliver J McElvaney; Kevin Molloy; Craig Hersh; Louise Clarke; Cedric Gunaratnam; Edwin K Silverman; Tomás P Carroll; Noel G McElvaney
Journal:  Am J Respir Crit Care Med       Date:  2020-07-01       Impact factor: 21.405

Review 4.  Alpha1-antitrypsin deficiency. 2: genetic aspects of alpha(1)-antitrypsin deficiency: phenotypes and genetic modifiers of emphysema risk.

Authors:  D L DeMeo; E K Silverman
Journal:  Thorax       Date:  2004-03       Impact factor: 9.139

Review 5.  Clinical considerations in individuals with α1-antitrypsin PI*SZ genotype.

Authors:  Gerard N McElvaney; Robert A Sandhaus; Marc Miravitlles; Gerard M Turino; Niels Seersholm; Marion Wencker; Robert A Stockley
Journal:  Eur Respir J       Date:  2020-06-18       Impact factor: 16.671

6.  Demographic and clinical characteristics of patients with α1-antitrypsin deficiency genotypes PI*ZZ and PI*SZ in the Spanish registry of EARCO.

Authors:  María Torres-Durán; José Luis López-Campos; Juan Luis Rodríguez-Hermosa; Cristina Esquinas; Cristina Martínez-González; José María Hernández-Pérez; Carlota Rodríguez; Ana Bustamante; Francisco Casas-Maldonado; Miriam Barrecheguren; Cruz González; Marc Miravitlles
Journal:  ERJ Open Res       Date:  2022-09-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.